OCS Stock Analysis: Buy, Sell, or Hold?
OCS - Oculis Holding AG Ordinary shares
$11.31
0.21 (1.94%)
▲
5d:
+5.56%
30d:
-62.59%
90d:
-56.55%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When OCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: OCS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: OCS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: OCS is currently trading at $11.30, which is considered oversold relative to its 30-day fair value range of $13.35 to $31.39.
Technical Outlook: Technically, OCS is in a downtrend. Immediate support is located at $10.52, while resistance sits at $16.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (82th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $38.05 (+243.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OCS is in a downtrend. Immediate support is located at $10.52, while resistance sits at $16.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (82th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $38.05 (+243.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.35 -
$31.39
Company Quality Score
50/100
(HOLD)
Options IV Signal
82th percentile
(ELEVATED)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 82th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 243.1% below Wall St target ($38.05)
Trading Range Analysis
30-Day Trading Range
$13.35 -
$31.39
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.20
(19.5%)
Support & Resistance Levels
Support Level
$10.52
Resistance Level
$16.00
Current Trend
Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.78
Wall Street Target
$38.05
(+243.1%)
Revenue Growth (YoY)
-26.7%
Share & Embed Analysis
Last updated: June 15, 2026 12:00 PM ET
Data refreshes hourly during market hours. Next update: 1:00 PM
Data refreshes hourly during market hours. Next update: 1:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
